Christian Fink, Presenter: Nothing to Disclose

Henrik Jakob Michaely MD, Abstract Co-Author: Nothing to Disclose

Harald Kramer MD, Abstract Co-Author: Nothing to Disclose

Konstantin Nikolaou MD, Abstract Co-Author: Nothing to Disclose

Bernd Juergen Wintersperger MD, Abstract Co-Author: Nothing to Disclose

Stefan Oswald Schoenberg MD, Abstract Co-Author: Nothing to Disclose

Olaf Dietrich, Abstract Co-Author: Nothing to Disclose

Maximilian Ferdinand Reiser MD, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

1. To give an overview about the physicochemical properties and pharmacokinetics of Gadofosveset trisodium in comparison to conventional MR contrast agents. 2. To review typical MRA protocols for Gadofosveset-enhanced MRA from head to toe 3. To discuss new imaging concepts based on the blood pool characteristics of Gadofosveset trisodium.

Gadofosveset trisodium (MS-325, VasovistTM , Schering AG) has recently been approved in Europe as the first blood pool contrast agent for MR angiography. The agent remains in the intravascular compartment due to a strong but reversible binding to plasma albumine. Compared to conventional MR contrast agents, Gadofosveset offers a 5-8 times higher relaxivity. In preclinical and clinical studies Gadovosfeset showed a good safety profile.

Gadofosveset is the first approved intravascular contrast agent for MR angiography. Due to a reversible binding to plasma albumine the agent acts as an intravascular contrast agent. Because of this, both, first-pass MRA and steady-state MRA can be performed.

Fink, C, Michaely, H, Kramer, H, Nikolaou, K, Wintersperger, B, Schoenberg, S, Dietrich, O, Reiser, M, et al, , MR Angiography with an Intravascular Contrast Agent (Gadofosveset Trisodium): Initial Clinical Experience and New Imaging Concepts.  Radiological Society of North America 2006 Scientific Assembly and Annual Meeting, November 26 - December 1, 2006 ,Chicago IL. http://archive.rsna.org/2006/4431329.html